Biotech’s near-term key catalysts

After sifting through big pharma's data reveals for the rest of 2022, Evaluate Vantage takes a look at the clinical results expected for biotech companies with a market cap of $1bn and above.

As with big pharma, Alzheimer's data represent the key event of the period. Biogen and Eisai have already toplined a positive result with lecanemab in early Alzheimer's, and detailed data are due at the CTAD conference in November. Apart from this, pivotal data from Madrigal could support an accelerated filing for resmetirom in Nash, while Arrowhead and Takeda’s RNAi project fazirsiran will yield results from its first placebo-controlled test in a rare liver condition. Ascendis, meanwhile, hopes to outshine Biomarin in young patients with achondroplasia.